Ondrejicková O, Dzurba A, Sedlák J, Tokárová J, Macicková T, Benes L
Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava, CSFR.
Biomed Biochim Acta. 1991;50(12):1251-4.
Administration of stobadine, a cardioprotective substance in investigation prevents a decrease in the content of protein SH groups and glutathione in hearts of rats treated with high doses of isoproterenol (ISO) (30 mg/kg). Moreover, stobadine also attenuated the increase in the content of malondialdehyde and activities of catalase and glutathione reductase as well as a diminution in the GSH/GSSG ratio observed in heart mitochondria isolated from ISO-treated animals. Since stobadine may be considered as a scavenger of reactive oxygen species (ROS), the above effects of the latter substance support the assumption about a possible involvement of reactive oxygen species (ROS) in some processes initiated by administration of ISO in doses inducing cardiac hypertrophy. However our results also indicate that ROS-mediated processes are not necessarily involved in the mechanism of induction of cardiac hypertrophy itself.
正在研究的一种心脏保护物质司托巴定给药后，可防止高剂量异丙肾上腺素（ISO，30mg/kg）处理的大鼠心脏中蛋白质SH基团和谷胱甘肽含量降低。此外，司托巴定还减弱了丙二醛含量的增加、过氧化氢酶和谷胱甘肽还原酶的活性，以及从ISO处理动物分离的心脏线粒体中观察到的GSH/GSSG比值的降低。由于司托巴定可被视为活性氧（ROS）清除剂，后一种物质的上述作用支持了活性氧（ROS）可能参与ISO诱导心脏肥大剂量给药引发的某些过程的假设。然而，我们的结果也表明，ROS介导的过程不一定参与心脏肥大本身的诱导机制。
